Condition (MeSH)
Neoplasms, Adnexal and Skin Appendage
ClinicalTrials.gov lists 8 trials for Neoplasms, Adnexal and Skin Appendage or a narrower condition beneath it. American College of Radiology Imaging Network has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 8 trials are tagged with Neoplasms, Adnexal and Skin Appendage itself; the rest are tagged with a narrower condition beneath it.
When did Neoplasms, Adnexal and Skin Appendage trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2013 | 1 |
| 2011 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neoplasms, Adnexal and Skin Appendage trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Not applicable | 3 |
| Observational | 3 |
How many Neoplasms, Adnexal and Skin Appendage trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Completed | 2 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neoplasms, Adnexal and Skin Appendage trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| American College of Radiology Imaging Network | 1 |
Which publications cover Neoplasms, Adnexal and Skin Appendage? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| SOX9 expression is a general marker of basal cell carcinoma and adnexal-related neoplasms. | Journal of cutaneous pathology | 2008 | Yes |
| Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2019 | No |
| Risk analysis of torsion and malignancy for adnexal masses during pregnancy. | Fertility and sterility | 2009 | No |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.
Not computed for conditions with fewer than 10 trials: drugs tested.